This article is total bs Kami (no disrespect to you). All it...

This article is total bs Kami (no disrespect to you). All it takes is 5 minutes looking at the results to see that cashflow is now not a problem. MYX has A$149M in cash and for the second half the ongoing businesses generated A$27.3M of positive cashflow ( -$19.2M 1st Half and total for the year +A$8.1M). If the businesses stood still for the next 12 months we would end up FY 25 with over A$200M of cash. We only have about A$10M of legacy costs to come and potentially a A$5-10M bill for legal defending the Imvexy patents.
I would like the company to continue its buy back as soon as possible and buy A$20-30M worth of stock before the AGM.

The FY24 results were mixed, obviously the cash generation and discipline was a plus, dermatology was a standout and now generating over 80% of revenue from branded products. The margin has now improved to 50%.

International is also on the mend and we may see further gains in FY 25.

The elephant in the room is WH, the second half performance was anaemic. There was only small revenue growth for Nextstellis and no growth at all for THMd products. Whilst there was script growth, the revenue was basically the same as the 1sthalf implying we are selling the products for less, margin has now slipped to 78% from high 80s.

For all the talk about the new WH sales team (4-6 months into the job), the results are not yet evident and we need this business unit to get back to the mid 20% growth/quarter for Nextstellis (slide 17) we saw in the first 9 months of calendar 2023 and some growth for THMD products . A continuation of current growth will see us delivering a mediocre result in FY 2025. Let's see what happens in the first quarter.

I remain positive about the stock and management but we need a quick turnaround in WH.